

Sue Cammarata

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4213769/sue-cammarata-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

34
papers

2,408
citations

21
h-index

36
g-index

36
ext. papers

2,733
ext. citations

4.7
avg, IF

4.58
L-index

#	Paper	IF	Citations
34	Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial. <i>International Journal of Infectious Diseases</i> , 2020 , 97, 374-379	10.5	5
33	Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	19
32	A Phase 3 Study to Compare Delafloxacin With Moxifloxacin for the Treatment of Adults With Community-Acquired Bacterial Pneumonia (DEFINE-CABP). <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofz514	11.6	15
31	Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections. <i>Clinical Infectious Diseases</i> , 2019 , 68, S223-S232	11.6	8
30	Efficacy and Safety of Single-Dose Oral Delafloxacin Compared With Intramuscular Ceftriaxone for Uncomplicated Gonorrhea Treatment: An Open-Label, Noninferiority, Phase 3, Multicenter, Randomized Study. <i>Sexually Transmitted Diseases</i> , 2019 , 46, 279-286	2.4	23
29	Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. <i>Journal of Infectious Diseases</i> , 2019 , 219, 1536-1544	7	26
28	A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study. <i>Clinical Infectious Diseases</i> , 2018 , 67, 657-666	11.6	57
27	Pharmacokinetics of Intravenous Delafloxacin in Patients With End-Stage Renal Disease. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 913-919	2.9	10
26	Clinical Pharmacokinetics of Sulfobutylether- β -Cyclodextrin in Patients With Varying Degrees of Renal Impairment. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 814-822	2.9	18
25	Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 514-521	2.9	17
24	Lack of phototoxicity potential with delafloxacin in healthy male and female subjects: comparison to lomefloxacin. <i>Photochemical and Photobiological Sciences</i> , 2018 , 17, 773-780	4.2	19
23	Safety of Delafloxacin: Focus on Adverse Events of Special Interest. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy220	1	21
22	Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	50
21	The Pharmacokinetics of the CYP3A Substrate Midazolam After Steady-state Dosing of Delafloxacin. <i>Clinical Therapeutics</i> , 2017 , 39, 1182-1190	3.5	22
20	Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 328-335	2.9	28
19	Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 3471-3480	5.1	67
18	A Global Phase 3 Study of Delafloxacin Compared to Vancomycin/Aztreonam in Patients with Acute Bacterial Skin and Skin Structure Infections. <i>Open Forum Infectious Diseases</i> , 2016 , 3,	1	5

17	Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers. <i>Clinical Therapeutics</i> , 2016 , 38, 53-65	3.5	37
16	Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age. <i>Clinical Therapeutics</i> , 2016 , 38, 39-52	3.5	36
15	A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 821-9	5.1	51
14	A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. <i>International Journal of Infectious Diseases</i> , 2015 , 30, 67-75	10.5	78
13	A thorough QT study to evaluate the effects of therapeutic and suprathreshold doses of delafloxacin on cardiac repolarization. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 3469-73	5.9	40
12	Results of a Global Phase 3 Study of Delafloxacin (DLX) Compared to Vancomycin With Aztreonam (VAN) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI). <i>Open Forum Infectious Diseases</i> , 2015 , 2,	1	8
11	Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. <i>Intensive Care Medicine</i> , 2004 , 30, 388-94	14.5	260
10	Linezolid vs Vancomycin *. <i>Chest</i> , 2003 , 124, 1789-1797	5.3	524
9	A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid. <i>American Journal of Surgery</i> , 2003 , 185, 369-75	2.7	33
8	Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. <i>Clinical Therapeutics</i> , 2003 , 25, 980-92	3.5	199
7	Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. <i>Clinical Infectious Diseases</i> , 2003 , 37, 1609-16	11.6	72
6	Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 1824-31	5.9	136
5	Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant <i>Staphylococcus aureus</i> nosocomial pneumonia. <i>Chest</i> , 2003 , 124, 1789-97	5.3	111
4	Linezolid versus ceftriaxone/cefepime in patients hospitalized for the treatment of <i>Streptococcus pneumoniae</i> pneumonia. <i>Scandinavian Journal of Infectious Diseases</i> , 2002 , 34, 720-8		51
3	Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. <i>Clinical Infectious Diseases</i> , 2001 , 32, 402-12	11.6	357
2	Acute mental changes in a 68-year-old man with bladder cancer. <i>Chest</i> , 1998 , 114, 621-3	5.3	4
1	Attenuation of Oxidant-Induced Lung Injury by 21-Aminosteroids (Lazaroids): Correlation with the mRNA Expression for E-Selectin, P-Selectin, ICAM-1, and VCAM-1. <i>Environmental Health Perspectives</i> , 1994 , 102, 193	8.4	1